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Abstract: The C677T and A1298C polymorphisms of methylenetatrahydrofolate reductase (MTHFR) gene are reported 
to have a relationship to methotrexate (MTX) metabolism, with conflicting results. The aim of this study was to determine 
the frequency of MTHFR C677 T and A1298C gene polymorphisms in a group of Turkish RA patients and evaluate its 
association with MTX toxicity. 
Sixty-four patients with RA and 31 control subjects with a mean age of 48.7 +12.5 and 46.2 + 13.4 years, were enrolled to 
the study. Demographic characteristics were obtained and MTX-related adverse effects were recorded in the patient 
group. The A1298C and C677T polymorphisms of the MTHFR gene were analyzed and the distribution of genotypes 
according side effects, were determined. 
The frequency of MTHFR C677T and A1298C polymorphisms were similar in the patient and control groups. Folic acid 
supplementation with a mean dose of 5mg folic acid/week, was present in all patients. Thirty-six of the 64 patients 
showed adverse effects to MTX treatment, and MTX had been discontinued in 12 (18.8%) patients due to side effects 
and/or inefficacy. MTHFR C677T and A1298C gene polymorphisms were found to be similar in patients with and 
without MTX-related adverse events. 
In conclusion, A1298C and C677T polymorphisms in the MTHFR gene, were not related with MTX-related toxicity in 
RA patients receiving folate supplementation. Further studies are needed to illuminate the polymorphisms in other 
enzymes that might be responsible from the MTX toxicity in patients suffering from RA. 
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INTRODUCTION 
  Rheumatoid arthritis is a chronic systemic rheumatic 
condition, characterized by joint inflammation, cartilage 
degradation and bone erosion. Methotrexate (MTX) is the 
cornerstone and the most common used disease-modifying 
antirheumatic drug (DMARD) for the treatment of RA and 
has been shown to reduce disease activity and stabilize the 
development of bone erosions [1]. Many aspects about the 
pharmacology of MTX are not clear. Despite the well 
accepted efficacy of MTX, response to the drug and adverse 
effects in RA patients are not universal. Although some 
patients experience good clinical response, some have to 
discontinue therapy due to adverse effects. At the present 
time there are no reliable tests or assessments that can 
predict the toxicity of MTX. A better understanding of its 
pharmacology can be gained by using the principles of 
pharmacogenetics to study genetic differences (polymor-
phisms) in the enzymes involved in the metabolic pathways 
of MTX [2-5]. There has recently been an interest in the 
association of folate pathway polymorphisms with the 
adverse events of MTX. In recent years several studies have 
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demonstrated polymorphism of the genes regulating 
enzymes in the intracellular MTX metabolic pathway, with 
conflicting results [6-21]. Two single nucleotide 
polymorphisms of methylene tetrahydrofolate (MTHFR) 
C677T and A1298C have been widely studied in the efficacy 
and/or toxicity of MTX [8-24]. 
  The aim of this study was to determine the frequency of 
MTHFR C677 T and A1298C gene polymorphism in a 
group of Turkish RA patients and evaluate its association 
with MTX toxicity. 
MATERIALS AND METHODS 
  A hundred and four patients with RA, who met the ACR 
revised criteria [25] for RA, were enrolled from the 
outpatient clinics of Ankara Training and Research Hospital, 
Rheumatology unit of Physical Medicine and Rehabilitation 
Clinic, between 2009 January and August 2009. Current or 
past treatment with MTX was the main criterion for the 
inclusion of RA patients into the study. Patients with a mean 
BMI>35, aged<18, and >80 years, having B12 and folic acid 
depletion and patients with these comorbid diseases (chronic 
renal failure, hepatic insufficiency, thyroid disease, heart 
failure and uncontrolled diabetes mellitus) were not included 
to the study. 104 patients with rheumatoid arthritis were 
assessed for eligibility. 98 patients had current or past MTX 
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29 patients were excluded due to age or comorbid diseases. 
Therefore 64 RA patients were included to the study. Thirty-
one age and sex similar (within + 2 years) healthy control 
subjects who were the members of the hospital staff and 
volunteered to participate in the study, were comprised. We 
obtained informed consent from all the patients and controls, 
and the study was approved by the ethics committee of the 
hospital. 
  Demographic characteristics including age, sex, body 
mass index of all subjects, and drug intake and disease 
duration of RA patients were recorded. All patients 
underwent a clinical interview and physical examination to 
determine MTX related adverse events. 
  Methotrexate-related adverse effects were defined as one 
or a combination of gastrointestinal symptoms (nausea, 
abdominal pain, diarrhoea) appearing repeatedly in 
association with methotrexate consumption, oral ulcers, 
disturbed liver function tests (alanine aminotransferase and 
aspartame aminotransferase more than twice the upper limit 
of normal values), methotrexate induced or aggravated skin 
nodules, and haematological adverse reactions (leucocyte 
count below 355/mm
3). Side effects were recorded during 
patient recruitment and from the files [12, 26]. 
  Blood samples of the patients were taken to determine 
hemoglobin (Hb), erythrocyte sedimentation rate (ESR) 
using the Westergren method, rheumatoid factor (RF) using 
nephelometric method and C reactive protein (CRP) by 
turbidimetric method in RA group. The numbers of tender 
and swollen joints as well as disease and treatment duration 
were collected from patient files. DAS 28 was calculated for 
each patient using well-known calculations which included 
the number of tender and swollen joints, ESR and patients’ 
global assessment of general health expressed on visual 
analog scale [27]. The scores of Health Assessment 
Questionnaire (HAQ) indicating the functional status of RA 
patients were recorded from the files [28]. The ESR, CRP, 
DAS28 and HAQ, were considered as disease activity 
parameters. 
  Genomic DNA was prepared from peripheral blood of 
patients and controls. The A1298C and C677T 
polymorphisms of the MTHFR gene were analyzed by 
polymerase chain reaction amplification, restriction enzyme 
digestion, and DNA fragment separation by electrophoresis, 
as described previously. Allelic frequencies and genotype 
distributions among groups were compared. The distribution 
of genotypes according to disease variables and side effects 
were also analyzed [29]. 
Statistical Analysis 
  Descriptive statistics were performed and indicated as 
mean +standard deviation and median (maximum-minimum) 
for continuous variables. All qualitative data are expressed 
as frequencies and percentages. The normality of the 
distribution of continuous variables was analyzed by Shapiro 
Wilk test. Differences in genotype distribution were tested 
with two sided chi-square test. The intergroup comparisons 
for continuous variables between the two groups (with and 
without polymorphism) were performed by student t test and 
Mann Whitney U test. Spearman’s correlation test was used 
to evaluate correlation between continuous variables and 
Pearson’s chi square test or Fisher’s exact outcome chi 
square tests were used to define the categorical variables. 
Kruskal Wallis test was performed for comparison of more 
than two groups. The level of significance was set to 0.05. 
All statistical analyses were done using SPSS for windows 
version 11.5 programme. 
RESULTS 
  A total of 64 RA patients and 31 control subjects were 
enrolled to the study. Characteristics of RA patients and 
control subjects are presented in Table 1. There was no 
statistical difference between the mean age, sex and BMI of 
the patient and control subjects (p>0.05). Most patients were 
receiving MTX at the time of enrollment but some had 
discontinued MTX treatment due to adverse effects. Folic 
acid supplementation with a mean dose of 5mg folic 
acid/week, was present in all patients. 
Table  1. Demographic and Clinical Characteristics of 
Patients and Controls 
 
  Patients  
(n=64) 
Controls  
(n=31) 
age (mean +SD) 48.7±12.5  46.2±13.4 
Sex (female/male)  53/11  26/5 
BMI( kg/m
2 ) 27.0±5.0  27.5±4.7 
Duration of the disease (years)  6.5 (0.50-34)   
Duration of MTX treatment (years)  2 (0.2-10)   
Concurrent DMARD treatment (n) (%)  34 (53.1%)   
Rheumatoid factor positivity (n)(%)  41( 64.1%)   
BMI: Body mass index, MTX: Methotrexate, DMARD: Disease-modifying 
antirheumatic drugs. 
 
  The mean duration and dose of the MTX were 2 years 
(0.2-10) and 15 mg/week (10-20) respectively. 34 (53.1%) 
patients were using MTX and other DMARDs. Of those 18 
(52.9%) patients were on sulphasalasine, 8 (23.5%) patients 
were on hydroxychloroquine, 2 (5.8%) patients were on 
leflunamide and 6 (17.6%) patients were on both HCQ and 
SLZ, in addition to MTX. 18 (28.1%) and 39 (60.9%) 
patients were using corticosteroids and NSAII drugs 
respectively. 38 (59.4%) patients were using oral MTX, 
while 26 (40.6%) patients were on subcutaneous MTX 
therapy. 
  Thirty-six of the 64 patients (56.2%) had experienced 
adverse effects to MTX treatment, of which gastrointestinal 
toxicity was the most common. MTX had been discontinued 
in 12 (18.8%) patients due to adverse side effects and/or 
inefficacy. Table 2 indicates the frequency of MTX-related 
adverse effects among the patients. There was no significant 
difference in the MTX dosage, the demographic and clinical 
features between the patients with and without adverse 
effects during MTX treatment (p>0.05). 
  The frequencies of MTHFR A1298C and C677T 
polymorphisms were determined in all subjects and were 
found to be statistically similar between patient and control 
groups (Table 3). The distribution of allele polymorphisms 
in regard to MTX-related adverse events were carried out. 
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found to be similar in patients with and without MTX-related 
adverse events (Table 4). In order to define the relationship 
between MTX-related side effects and polymorphisms in 
MTHFR genes, we have analyzed the patients receiving only 
MTX treatment. The distribution of MTHFR A1298C and 
C677T polymorphisms in patients with and without adverse 
effects, were again found to be similar (Table 5). 
Table  2.  The Frequency of Methotrexate-Related Adverse 
Effects in Patients with Rheumatoid Arthritis 
 
 n  (%) 
General 
Fatigue 
Malaise  
 
18(28.1%) 
14(21.9%) 
Gastrointestinal 
Nausea or vomiting 
Disturbed liver function tests  
 
20(31.3%) 
6(9.4%) 
Haematological   2 (3.1%) 
Pulmonary 5  (7.8%) 
Mucocutaneous 15  (23.4%) 
Ear, nose, throat  3 (4.7%) 
Neuropsychiatric   2 (3.1%) 
 
  The distribution of disease activity parameters in regard 
to allele polymorphisms, were also determined. No statistical 
difference between ESR, CRP, HAQ and DAS 28 values in 
regard to MTHFR A1298C (Table 6) and C677T (Table 7) 
polymorphisms were observed in the patient group. 
DISCUSSION 
  This study showed that the frequency of MTHFR 
A1298C and C677T polymorphisms were similar in Turkish 
RA patients and healthy control subjects. The prevalence of 
the MTHFR C677T and A1298C genotypes in our cohort of 
patients were 45% for 677CC, 43% for C677T and 10% for 
677TT, and 37% for 1298AA, 48% for 1298AC, and 14% 
for 1298CC; which were comparable with some previous 
results [12, 14, 19]. 
 The frequency of the C677T polymorphism 
homozygosity was lower in our study as compared to 
previous studies which could be related to ethnic differences 
[18]. Ghodke et al. and Berkun et al. determined a 
significantly higher incidence of A1298C polymorphism in 
their RA group than in general population [9, 16]. 
  The present study shows that genetic polymorphisms in 
the MTHFR gene do not influence the toxicity of MTX 
treatment in RA patients receiving folate supplementation. 
The influence of MTHFR C677T and 1298C polymorphisms 
on the toxicity of MTX treatment has been widely studied, 
however conflicting results have been reported [8-19]. In 
some previous studies the presence of MTHFR A1298C 
polymorphism was associated with a higher incidence of 
MTX-related toxicity. Wessels et al. observed more adverse 
events in MTHFR 1298C allele carriers in their early RA 
patients as also confirmed by study group of Derwieux et al. 
and Mena et al. [11, 14, 24]. On the other hand, Grabar et al. 
reported a protective effect of MTHFR A1298C 
polymorphism on overall MTX toxicity, and MTHFR 
Table 3.  The Distribution of Genotypes (A1298C and C677T Polymorphisms) in RA and Control Groups 
 
  RA (n=64)   Control (n=31)  p   Odds Ratio (% CI) 
677 CC  29 (45.3%)  20 (64.5%)  -  1.000
a 
677 CT  28 (43.8%)  10 (32.3%)  ns  1.931 (0.770-4.844) 
677 TT  7 (10.9%)  1 (3.2%)  ns  4.828 (0.550-42.339) 
1298 AA  24 (37.5%)  6 (19.4%)  -  1,000
a 
1298 AC  31 (48.4%)  16 (51.6%)  ns  0.484 (0.165-1.425) 
1298 CC  9 (14.1%)  9 (29.0%)  0.035  0.250 (0.069-0.905) 
CI: condidence interval a reference category. 
aReference Genotype. 
Table 4.  The Genotypic Distribution of RA Patients According to Presence of Adverse Events 
 
  Adverse Events (-) (n=28)   Adverse Events (+) (n=36)   P  Odds Ratio (%95 CI) 
677 CC  12 (42.9%)  17 (47.2%)  -  1,000
a 
677 CT  13 (46.4%)  15 (41.7%)  ns  0.814 (0.286-2.322) 
677 TT  3 (10.7%)  4 (11.1%)  ns  0.941 (0.177-4.997) 
1298 AA  12 (42.9%)  12 (33.3%)  -  1,000
a 
1298 AC  11 (39.3%)  20 (55.6%)  ns  1.818 (0.613-5.391) 
1298 CC  5 (17.9%)  4 (11.1%)  ns  0.800 (0.172-3.728) 
CI: Confidence interval a Reference category. 
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1298CC genotype was found to be inversely associated with 
MTX-related adverse events in some previous studies [15, 
16]. MTHFR C677T polymorphism was also reported to be 
associated with MTX-related adverse events in some 
previous studies [8, 10, 19, 21]. Spelatos et al. illustrated an 
inverse relationship between MTHFR C677T polymorphism 
and MTX related toxicity in a group of patients with 
autoimmune diseases in which the presence of toxicity was 
more common in patients with the normal 677CC genotype 
[12]. In contrast to these studies, no association between the 
C677T and/or A1298C polymorphisms and MTX-related 
side effects was reported by some previous authors, 
supporting our results [9, 12, 13, 16, 17]. Our results are in 
agreement also with the findings of Ghodke et al. and 
Taraborelli et al. that neither MTHFR A1298C nor C677T 
polymorphisms have associated with MTX-related adverse 
effects in Turkish RA patients, similar to Indian and Italian 
RA groups [9, 17]. In a recent meta-analysis with a total of 
1514 patients with RA, no association was determined 
between the C677T and A1298C polymorphisms of MTHFR 
gene and the toxicity of MTX in RA patients [20]. 
  The discordance and inconsistency of some previous 
studies and our data can be explained by the characteristics 
of the study group, therapeutic doses and particularly the 
prescription of folate supplementation. In the earlier studies 
the doses used for MTX treatment were lower and majority 
of the patients were not receiving folate supplementation and 
the proportion of patients who had discontinued MTX due to 
adverse effects were much higher than in our study [8, 10, 
19]. Similar to our data, majority of the patients in some   
previous studies, were receiving concomitant folic acid and 
discontinuation rates of MTX due to adverse events, were 
comparable to the results of our study [12-14, 17]. This can 
be due to the counteracting effects of folate supplementation 
on deleterious effects of these MTHFR gene polymorphisms 
in patients with RA on MTX treatment. The molecular basis 
for this effect could be the protection of MTHFR enzyme 
from thermal inactivation by folate supplementation [13, 14]. 
Our study strengthens the role of folic acid supplementation  
 
Table  5.  The Genotypic Distribution According to Adverse 
Events in Patients Receiving Only Methotrexate 
Treatment 
 
  Adverse Events (-)  
(n=13) 
Adverse Events (+)  
(n=17)  
p 
1     ns
a 
677 CC  7 (53.8%)  9 (52.9%)   
677 CT  4 (30.8%)  5 (29.4%)   
677 TT  2 (15.4%)  3 (17.6%)   
2     ns
a 
1298 AA  8 (61.5%)  5 (29.4%)   
1298 AC  4 (30.8%)  9 (52.9%)   
1298 CC  1 (7.7%)  3 (17.6%)   
aComparisons in terms of the distibutions of genotypes. 
Likelihood ratio test. 
 
on preventing the toxicity of MTX even in patients that had 
Table 6.  The Distributions of Disease Activity Parameters According to MTHFR C677T Polymorphism in RA Patients 
 
  CC (n=29)  CT (n=28)  TT (n=7)  p
a 
HAQ (median)  0.75 (0-3)  0.9 (0-3)  0.25 (0-1.75)  0.239 
DAS28 (median)  4.1 (1,9-7,8)  4.2 (1.7-7.5)  4.2 (2.7-5.4)  0.735 
Larsen Score (median)  2.0 (1.0-5.0)  2.5 (1.0-5.0)  2.0 (1.0-5.0)  0.654 
ESR (median)  39.0 (3.0-82.0)  25.0 (2.0-120.0)  38.0 (13.0-57.0)  0.197 
CRP (median)  0.9 (0.2-10.5)  0.6 (0.1-10.0)  0.7 (0.3-1.9)  0.284 
aAnalysis of variance among the genotypes b Comparisons between CC and CT+TT. 
HAQ: The Health Assessment Questionnaire, DAS 28: Disease Activity Score, ESR: erythrocyte sedimentation rate, CRP: C- reactive protein, MTX: Methotrexate, DMARD: 
Disease-modifying antirheumatic drugs. 
NSAII: Nonsteroidal anti-inflammatory drugs. 
 
Table 7.  The Distribution of Disease Activity Parameters According to MTHFR A1298C Polimorphism in RA Patients 
 
  AA (n=24)  AC (n=31)  CC (n=9)  p
a 
HAQ (median)  0.5 (0-2.5)
b  1.1 (0-3)
b,c  0.25 (0-1.6)
c  0.005 
DAS28 (median)  4.1 (2.4-6.9)  4.3 (1.7-7.8)  3.4 (2.6-5.8)  0.347 
Larsen Score (median)  2.0 (1.0-5.0)  3.0 (1.0-5.0)  2.0 (1.0-5.0)  0.220 
ESR (median)  26.5 (6.0-120.0)  36.0 (2.0-110.0)  29.0 (3.0-50.0)  0.344 
CRP (median)  0.7 (0.2-10.0)  0.8 (0.1-10.5)  0.5 (0.2-2.5)  0.386 
aAnalysis of variance among the genotypes 
bStatistically significant difference between AA and AC (p=0,003). 
cStatistically significant difference between AC and CC (p=0,002). 
HAQ: The Health Assessment Questionnaire, DAS 28: Disease Activity Score, ESR: Sedimentation, CRP: C- reactive protein, MTX: Methotrexate, DMARD: Disease-modifying 
antirheumatic drugs, NSAII: Nonsteroidal anti-inflammatory drugs. 34   The Open Rheumatology Journal, 2011, Volume 5  Taba et al. 
polymorphisms in MTHFR gene. Polymorphisms in 
enzymes other than MTHFR may have some correlation with 
the clinical toxicity of MTX in RA patients particularly on 
folate supplementation and needs to be further studied. 
  MTX inhibits the enzyme dihydrofolate reductase, 
thereby depleting the pool of reduced folates and producing 
a state of effective folate deficiency. Folic acid 
supplementation was shown not to antagonize the 
therapeutic response but there is no definite consensus 
regarding the use of folate supplements in patients taking 
MTX. Regional and national differences in practice remain 
pronounced. Folic acid improves MTX tolerability rates 
without compromising efficacy. 5mg/day folic acid has been 
proposed to be given in all patients receiving MTX therapy 
[30, 31]. In our study all of the patients were on concomitant 
folic acid supplementation, which might be a limitation of 
our study. It would be valuable to study these gene 
expressions according to side effects of MTX, in both 
patients on folate supplementation and in patients not 
receiving this supplementation. 
  Our results also indicate that the disease activity 
parameters, which may be a reflection of MTX efficacy, 
were similar between the groups with and without 
polymorphisms in MTHFR A1298C and C677T genes. 
Similar to our study, most of the previous studies have not 
found any association between C677T and A1298 C 
polymorphisms and efficacy of MTX treatment in RA 
patients [9, 17, 20, 23]. On the other hand, Kurzawski et al. 
[22] indicated an association with MTHFR 677T and 1298C 
alleles, and increased rate of remission in RA patients treated 
with MTX, supporting some of the previous reports [8, 14]. 
  In conclusion, A1298C and C677T polymorphisms in the 
MTHFR gene, were not related with MTX toxicity in 
Turkish RA patients receiving folate supplementation. 
Further studies are needed to illuminate the polymorphisms 
in other enzymes that might be responsible from clinical 
toxicity of MTX in patients suffering from RA. 
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